Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05210504 · ClinicalTrials.gov registry record · Phase 1
Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3
A Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT05210504 is a Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 23 participants.
The verdict
NCT05210504, a Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study aims to assess the effect and breakdown of lysine administration, specifically examining whether it leads to increased plasma 2-AAA in healthy humans.
Interventions
- DRUG Normal Saline
- DRUG L-Lysine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2023-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05210504
The ClinicalTrials.gov registry entry for NCT05210504 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT05210504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05210504 about?
NCT05210504 is a clinical study titled "Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3". This study aims to assess the effect and breakdown of lysine administration, specifically examining whether it leads to increased plasma 2-AAA in healthy humans.
What is the current status of trial NCT05210504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2022-03-09. Estimated completion is 2023-01-27.
What interventions are being tested in trial NCT05210504?
The interventions under investigation include: Normal Saline (DRUG), L-Lysine (DRUG).
Who is sponsoring clinical trial NCT05210504?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.